Abstract：Objective To investigate the clinical effect of Budesonide combined with Doxofylline in the treatment of chronic obstructive pulmonary disease.Methods A total of 90 patients with chronic obstructive pulmonary disease admitted to Liangxiang Hospital of Fangshan District, Beijing from May 2017 to June 2019 were selected as the research objects.According to random number table method, they were divided into the observation group and the control group,with 45 cases in each group.The observation group was given Budesonide combined with Doxotheophylline, while the control group was given routine treatment, the treatment period was 10 d.The therapeutic effect, pulmonary function indexes, arterial blood gas indexes and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.78%, which was higher than that of the control group(68.89%), and the difference was statistically significant (P＜0.05).There were no significant differences in forced expiratory volume in one second (FEV1) and forced expiratory volume in one second/forced vital capacity (FEV1/FVC) between the two groups before treatment (P＞0.05).After treatment, FEV1 and FEV1/FVC in the two groups were higher than those before treatment, FEV1 and FEV1/FVC in the observation group were higher than those in the control group,and the differences were statistically significant (P＜0.05).Before treatment, there were no significant differences in blood oxygen partial pressure (PaO2) and arterial carbon dioxide partial pressure (PaCO2) between the two groups (P＞0.05).After treatment, PaO2 levels in two groups were higher than those before treatment, PaCO2 levels were lower than those before treatment, PaO2 in the observation group was higher than that in the control group, PaCO2 was lower than that in the control group, and the differences were statistically significant (P＜0.05).The total incidence of adverse reactions in the observation group was 6.67%, which was lower than that in control group (22.22%), and the difference was statistically significant (P＜0.05).Conclusion Budesonide combined with Doxofylline can be used for the treatment of chronic obstructive pulmonary disease with fewer adverse events.It is safe and has clinical application value.
Ferguson GT，Tashkin DP，Sko rby T，et al.Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease：The 6-month，randomized RISE （Revealing the Impact of Symbicort in reducing Exacerbations in COPD） study[J].Respir Med，2017，132：31-41.
京公网安备 11010502046607号